Physician profile
Caroline Hamrick
NPI 1225092398
$1,678.23
in general payments reported to CMS, 2019-2025
34 companies · $273 in 2025
The $273 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $21.50 · 2023: $702 · 2024: $681 · 2025: $273.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,657.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,656.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $212.25 | 2023-2025 | |
| Janssen Biotech, INC. | $116.31 | 2023-2024 | Erleada, Darzalex, Imbruvica |
| Merck Sharp & Dohme LLC | $105.29 | 2023-2024 | Keytruda |
| Daiichi Sankyo INC. | $95.73 | 2023-2024 | Enhertu |
| Genentech USA, INC. | $84.07 | 2023-2024 | Rozlytrek, Tecentriq, Alecensa |
| Sobi, INC | $79.39 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $77.79 | 2023-2024 | Libtayo |
| Genzyme Corporation | $69.88 | 2023-2024 | |
| Astrazeneca Pharmaceuticals LP | $68.92 | 2024-2025 | Tagrisso |
| Dilon Technologies, INC. | $62.50 | 2025 | Hemoblast Bellows |
| Bayer Healthcare Pharmaceuticals INC. | $58.86 | 2023 | |
| Seagen INC. | $56.45 | 2023 | Adcetris, Padcev |
| Eisai INC. | $54.07 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.96 | 2024-2025 | |
| Sumitomo Pharma America, INC. | $37.51 | 2023-2024 | Orgovyx |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $34.82 | 2023-2024 | Ultomiris |
| Smith+Nephew, INC. | $32.53 | 2023-2025 | Grafix Pl, Stravix, Grafix |
| Emd Serono, INC. | $32.18 | 2024-2025 | |
| Exelixis INC. | $31.77 | 2024 | Cabometyx |
| Karyopharm Therapeutics INC. | $31.39 | 2023 | Xpovio |
| Takeda Pharmaceuticals U.S.A., INC. | $29.56 | 2023 | Iclusig |
| Adc Therapeutics America, INC. | $29.00 | 2024 | |
| Novartis Pharmaceuticals Corporation | $26.11 | 2024 | |
| Taiho Oncology, INC. | $24.02 | 2023 | |
| Edwards Lifesciences Corporation | $21.50 | 2022 | |
| Pharmacosmos Therapeutics INC. | $19.86 | 2024 | Cosela |
| Kyowa Kirin, INC. | $19.37 | 2023 | Poteligeo |
| Incyte Corporation | $18.69 | 2023 | Jakafi |
| G1 Therapeutics, INC. | $18.30 | 2023 | Cosela |
| Agios Pharmaceuticals, INC. | $17.70 | 2024 | |
| Deciphera Pharmaceuticals INC. | $17.51 | 2023 | Qinlock |
| Conmed Corporation | $16.81 | 2025 | Airseal |
| Beigene USA, INC. | $16.10 | 2024 | Tevimbra |
| Amgen INC. | $15.03 | 2023 | Lumakras |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caroline Hamrick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.